{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:36:25Z","timestamp":1792132585097,"version":"4.4.0"},"reference-count":52,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["10.13039\/501100001809"],"award-info":[{"award-number":["10.13039\/501100001809"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Provincial Clinical Research Center for Digestive Diseases","award":["2020B1111170004"],"award-info":[{"award-number":["2020B1111170004"]}]},{"name":"National Key Clinical Discipline"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in metastatic gastric cancer. Their potential benefits in the neoadjuvant therapy for advanced gastric cancer (AGC) are promising but require real-world evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>We aimed to assess the real-world impact of adding ICIs to neoadjuvant chemotherapy (NAC) in AGC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This is a retrospective, propensity score-matched analysis of 580 AGC patients treated with NAC, with or without ICIs, followed by radical gastrectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients were matched using propensity score matching (PSM) to balance baseline characteristics. Pathological complete response (pCR) rates and toxicity were compared between the ICIs-Chemo and Chemo cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      After PSM, 188 patients were included: 71 in the ICIs-Chemo cohort and 117 in the Chemo cohort. Chemotherapy regimens in both cohorts included SOX (49.5%, 93\/188), FLOT (26.6%, 50\/188), XELOX (12.8%, 24\/188), and FOLFOX (11.2%, 21\/188). The ICIs used were predominantly Sintilimab (67.6%, 48\/71), followed by Tislelizumab (21.1%, 15\/71), Nivolumab (7%, 5\/71), and others (4.2%, 3\/71). Adding ICIs to NAC significantly improved the pCR rate (ICIs-Chemo: 29.6% vs. Chemo: 13.7%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.014). The SOX regimen, with (37.1%, 13\/35) or without ICIs (22.4%, 13\/58), demonstrated the highest pCR rates. Subgroup analysis indicated that patients older than 60\u2009years (OR\u2009=\u20093.86,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and those with moderately\/well-differentiated tumors (OR\u2009=\u20094.27,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.01) may derive greater benefit from adding ICIs. While overall toxicity and surgical complication rates were similar between cohorts, we observed two cases of suspected severe immune-related adverse events (irAEs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Adding ICIs to NAC regimens in AGC significantly improves pathological response. While overall toxicity is not increased, close monitoring for irAEs is necessary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251346423","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T08:15:02Z","timestamp":1752653702000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Immune checkpoint inhibitors improve the efficacy of neoadjuvant chemotherapy in advanced gastric cancer: a retrospective cohort study"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-3872","authenticated-orcid":false,"given":"Yonghe","family":"Chen","sequence":"first","affiliation":[{"name":"Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-0128","authenticated-orcid":false,"given":"Jianwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, 26 Yuancun Erheng Road, Guangzhou 510655, China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7129-8954","authenticated-orcid":false,"given":"Junsheng","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, 26 Yuancun Erheng Road, Guangzhou 510655, China"},{"name":"Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goab010"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.045"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2000.01360.x"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61873-4"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.5908"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318216f449"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.0597"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00297-7"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3850"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199903000-00001"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"issue":"4","key":"e_1_3_4_17_2","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer","author":"Fuchs CS","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer. JAMA Oncol 2018; 4:e180013.","journal-title":"JAMA Oncol"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.959295"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.075"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.074"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4062"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4055"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02721-w"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4151"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388"},{"key":"e_1_3_4_28_2","unstructured":"Standing Committee of the National People\u2019s Congress. Physician Law of the People\u2019s Republic of China https:\/\/www.gov.cn\/xinwen\/2021-08\/20\/content_5632496.htm (2021 accessed October 20 2024)."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0393-7"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02176.x"},{"key":"e_1_3_4_31_2","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm (2020 accessed 19 February 2024)."},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-014-2525-1"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0008"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-022-01331-8"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v13.i12.2161"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4084-9"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.02.002"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.09.001"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41604"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.8595"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0021"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4000"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126908"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112839"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00348-4"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z"},{"key":"e_1_3_4_53_2","first-page":"5006","article-title":"PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial","volume":"11","author":"Sun Y-T","year":"2021","unstructured":"Sun Y-T, Guan W-L, Zhao Q, et al. PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. Am J Cancer Res 2021; 11: 5006\u20135015.","journal-title":"Am J Cancer Res"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251346423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251346423","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251346423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:32:37Z","timestamp":1777588357000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251346423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":52,"alternative-id":["10.1177\/17588359251346423"],"URL":"https:\/\/doi.org\/10.1177\/17588359251346423","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17588359251346423"}}